Investigational drug · Phase 3
CM313
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
15
Any phase or sponsor naming "CM313"
First trial start
2024
Nov 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CM313", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus
- Primary Immune Thrombocytopenia
- Platelet Transfusion Refractoriness
- Aplastic Anemia
- Multiple Myeloma (MM)
- IgA Nephropathy
Approved drugs for the same conditions: Multiple myeloma · Anemia · Immune thrombocytopenia · Lupus (SLE) · IgA nephropathy · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "CM313" as an intervention, largest first.
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07910903 · 320 participants (planned) · Start Dec 2026 · Primary completion May 2030
Drug: CM336; CM313 and 3 more · For: Multiple Myeloma (MM)
Sites: Tianjin, China
- Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)Pivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT06791772 · 150 participants (planned) · Start Feb 2025 · Primary completion Oct 2026
Drug: CM313 injection; CM313 injection and 1 more · For: Systemic Lupus Erythematosus
Sites: Beijing, China
- Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic AnemiaPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT06791824 · 125 participants (planned) · Start Mar 2025 · Primary completion Dec 2027
Drug: CM313(SC) injection; CM313(SC) injection and 1 more · For: Aplastic Anemia
Sites: Tianjin, China
Keymed Biosciences Co.LtdIndustry
NCT06126237 · 120 participants (planned) · Start Feb 28, 2024 · Primary completion Feb 28, 2026
Drug: CM313 injection · For: Multiple Myeloma
- Study of CM313(SC) Injection in Subjects With Platelet Transfusion RefractorinessPivotal-lookingRecruiting
Keymed Biosciences Co.LtdIndustry
NCT06792019 · 110 participants (planned) · Start Mar 25, 2025 · Primary completion Nov 16, 2027
Drug: CM313(SC) injection-low dose; CM313(SC) injection-high dose · For: Platelet Transfusion Refractoriness
Sites: Tianjin, China
- Study of CM313 in Subject With IgA NephropathyPivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT06830395 · 106 participants (planned) · Start Sep 2025 · Primary completion Mar 2027
Drug: CM313; Placebo · For: IgA Nephropathy
Sites: Beijing, China
- A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.Pivotal-lookingStatus unknown
Chao JiAcademic, hospital or other
NCT06663943 · 100 participants (planned) · Start Oct 1, 2025 · Primary completion Oct 30, 2026
Drug: CM313 (SC); Glucocorticoids · For: Pemphigus Disease; Pemphigus Vulgaris (PV)
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaStatus unknown
Keymed Biosciences Co.LtdIndustry
NCT04818372 · 87 participants (planned) · Start Apr 26, 2021 · Primary completion Jan 2023
Drug: CM313-Dose escalation; CM313 and 2 more · For: Multiple Myeloma; Lymphoma
Sites: Beijing, China · 3 sites in all
- Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)Active, not recruiting
Keymed Biosciences Co.LtdIndustry
NCT06594146 · 62 participants · Start Nov 11, 2024 · Primary completion Dec 30, 2025
Drug: CM313 injection · For: Primary Immune Thrombocytopenia
Sites: Tianjin, China
- Study of CM313 in Healthy SubjectsStatus unknown
Keymed Biosciences Co.LtdIndustry
NCT06285227 · 51 participants (planned) · Start Mar 12, 2024 · Primary completion Apr 30, 2025
Drug: CM313 injection · For: Healthy
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial.
Zhao J, Lin C, Xie Q, et al. · Signal Transduct Target Ther 2025
- Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.
Chen Y, Xu Y, Dai J, et al. · BMJ 2025
- Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM313 in Healthy Participants: An Open-Label/Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial.
Yu S, Wu J, Zhao J, et al. · Clin Transl Sci 2025
- CM313 Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma or Marginal Zone Lymphoma: A Multicenter, Phase 1 Dose-Escalation and Dose-Expansion Trial.
Zhou H, Huang Z, Fang B, et al. · Am J Hematol 2025
- A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
Chen Y, Xu Y, Li H, et al. · N Engl J Med 2024
- Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
Liu W, Yu J, Sun K, et al. · Front Immunol 2024
Also in development for Systemic Lupus Erythematosus
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- FrexalimabSAR441344Phase 39 trials
Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- MIL62Phase 34 trials
Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy
- ObexelimabPhase 34 trials
Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis
- Rese-celCABA-201Phase 34 trials
Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AfimetoranBMS-986256, BLN-256Phase 32 trials
Beeline Medicines Corporation · Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.